Sevion Therapeutics

Tetragenetics launches mAbs partnership program

Friday, December 18, 2015

Tetragenetics, an emerging biotechnology company engaged in the expression of ion channel drug targets, has announced a new partnership program for the discovery and development of therapeutic monoclonal antibodies (mAbs) directed against well-known ion channel drug targets implicated in a wide range of disease states—such as pain and autoimmune disorders.

[Read More]